anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Routine vaccinations help prevent the outbreak and spread of infectious diseases; however, it can take up to ten years from vaccine approval to introduction into routine vaccination schedules in Japan. Here, we investigate the information required to introduce an approved vaccine into routine vaccination schedules and the reasons why it takes so long. Based on the published data of the Immunization and Vaccine Committee of the Health Science Council, we set out to explore ways to facilitate discussion on this topic. The following issues were identified as discussion points: disease burden, efficacy and safety, and cost-effectiveness. Until now, epidemiological information has been used to evaluate the efficacy of vaccines, and also to evaluate the safety in the presence of notable adverse reactions. However, in some cases, it took a long time to obtain epidemiological information regarding the frequency of rare but serious adverse reactions and the need for a booster dose. Given the risk of spreading infectious diseases due to delays in decision-making, vaccines may have to be introduced into routine vaccination schedules based on the results of clinical trials that can be obtained in a relatively short period. In contrast, epidemiological information is necessary to evaluate the disease burden, frequency of adverse reactions, and the necessity of booster doses. Therefore, developing an epidemiological information collection system is urgently required.
This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo a instrumental swallowing evaluation (videofluoroscopy). The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
A complex and evolutionary process that involves the buildup of lipids in the arterial wall and the invasion of inflammatory cells results in atherosclerosis. Cell death is a fundamental biological process that is essential to the growth and dynamic equilibrium of all living things. Serious cell damage can cause a number of metabolic processes to stop, cell structure to be destroyed, or other irreversible changes that result in cell death. It is important to note that studies have shown that the two types of programmed cell death, apoptosis and autophagy, influence the onset and progression of atherosclerosis by controlling these cells. This could serve as a foundation for the creation of fresh atherosclerosis prevention and treatment strategies. Therefore, in this review, we summarized the molecular mechanisms of cell death, including apoptosis, pyroptosis, autophagy, necroptosis, ferroptosis and necrosis, and discussed their effects on endothelial cells, vascular smooth muscle cells and macrophages in the process of atherosclerosis, so as to provide reference for the next step to reveal the mechanism of atherosclerosis.
PROBLEM TO BE SOLVED: To provide a medical care system in which appropriate advises of medical doctors can be informed to a caring person without giving any anxiety to a patient. SOLUTION: Installed type terminal units 300a to 300m which received indication of starting measurement of vital information from a center device 200 begin electrocardiogram and heart rate measurements as well as blood pressure measurement. Results of measurements and recorded results of trends, recall and alarm of measurement parameters are transmitted to the center device 200. In addition, TV cameras are provided to patient and doctor devices to enable the doctor to grasp changes of the condition of the patient by looking at his vital signs and give various advises to the patient directly. When some special core is necessary, it is informed to a caring person directly without sounding an alarm nor displaying it on the terminal units 300a to 300m which the patient can confirm visually. When some urgent treatment is necessary, an adequate method is instructed to the caring person.
This intervention arm will receive a total of 5 doses of Minocycline. Dose 1 of Minocycline will be 400mg IV within 12-hours of onset of symptoms. Dose 2 of Minocycline will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
PURPOSE OF REVIEW: Given the rapid development of multiple targeted and immune therapies for patients with advanced melanoma, it can be challenging to select a therapy based on currently available data. This review aims to provide an overview of frontline options for metastatic melanoma, with practical guidance for selecting a treatment regimen.
RECENT FINDINGS: Recently reported data from randomized trials suggests that the majority of patients with unresectable melanoma should receive a PD-1 checkpoint inhibitor as part of their first line therapy, irrespective of BRAF mutation status. Additional data also suggests that combination immunotherapies result in improved outcomes compared to single agent, albeit at the cost of increased toxicity, though to date no biomarker exists to help guide treatment selection. As the number therapeutic options continue to grow for patients with advanced melanoma, there is likely to be a continued focus on combination strategies. Defining the optimal treatment approach in order to maximize efficacy while minimizing toxicity remains an area of active investigation.
Dr. Teal's Sleep Lotion with Melatonin, Lavender, and Chamomile. 3 g lotion applied to one arm (without washing for at least 4 hours).
One hundred and twenty patients at age range from 18 to 60 undergoing laparotomy was enrolled in this study. Patients were randomly assigned to two groups 60 in epidural group and the other 60 patients in rectus catheter group. epidural catheter inserted pre induction but rectus sheath catheter inserted by the surgeon at the end of surgery. In both groups we activated with10 ml bupivacain25% before patient recovery then 10 ml bupivacain.125% each 6 hours. If patient still in pain 1gm perflgan injected. If patient still in pain 10 mg nalufine for 70 kg patient injected. we will record pulse, blood pressure and visual analogue scale at 0,6,12,24 and 36 hours postoperative. Also Occurrence of nausea and vomiting, Time of return of bowel movement, Time of discharage and amount of analgesia used will be recorded. Results, discution will be later.
Labelled antibodies against reagin Ig or against fragments of reagin Ig are used to determine reagin Ig (reagins are antibodies against allergens). The antibodies may be labelled with a radioactive isotope, for example I125, or with a fluorescent group using for example fluorescein isothiocyanate. Means for determining reagins comprises a first reagent comprising a water-insoluble polymer having bound to it allergen against which the reagin to be determined is directed and a second reagent comprising the labelled antibodies as above. The sample is incubated with the first reagent when any reagin present in the sample becomes attached to the polymer particles the polymer particles are separated from the liquid phase, washed and then incubated with the second reagent. The solid and liquid phases are separated again and the radiation in either phase determined and compared with that in a control. The water-insoluble polymer is preferably particulate but may be in the form of discs, strips or a test tube wall and may be a copolymer of a polyhydroxy compound for example dextran, starch, dextrins, polyvinylalcohol with a bifunctional substance. The allergen may be physically or chemically bound to the polymer. Examples relate to Sephadex (RTM) as carrier, birch pollen as allergen and I125-labelled rabbit antibody.
The International Parkinson and Movement Disorder Society (MDS) created a task force (TF) to provide a critical overview of the Parkinson's disease (PD) subtyping field and develop a guidance on future research in PD subtypes. Based on a literature review, we previously concluded that PD subtyping requires an ultimate alignment with principles of precision medicine, and consequently novel approaches were needed to describe heterogeneity at the individual patient level. In this manuscript, we present a novel purpose-driven framework for subtype research as a guidance to clinicians and researchers when proposing to develop, evaluate, or use PD subtypes. Using a formal consensus methodology, we determined that the key purposes of PD subtyping are: (1) to predict disease progression, for both the development of therapies (use in clinical trials) and prognosis counseling, (2) to predict response to treatments, and (3) to identify therapeutic targets for disease modification. For each purpose, we describe the desired product and the research required for its development. Given the current state of knowledge and data resources, we see purpose-driven subtyping as a pragmatic and necessary step on the way to precision medicine. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
PCT No. PCT/EP94/02531 Sec. 371 Date Jul. 15, 1996 Sec. 102(e) Date Jul. 15, 1996 PCT Filed Jul. 29, 1994 PCT Pub. No. WO95/08323 PCT Pub. Date Mar. 30, 1995Disclosed are budesonide pellets with a controlled release pattern containing, from the inside to the outside: a) neutral pellets; b) an active principle layer of micronized budesonide and one or more water-soluble auxiliaries; c) a first lacquer coating consisting of 80 to 97% of at least one lacquer insoluble in gastric fluids but soluble in intestinal fluids and 3 to 20% of at least one lacquer insoluble in both gastric and intestinal fluids; and d) a second lacquer coating consisting of at least one lacquer insoluble in gastric and intestinal fluids. The invention also relates to a process for producing budesonide pellets with a controlled release pattern.
R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28.
Due to pandemic-induced lockdown(s) in 2020, dyslexia treatment was forced to move to online platforms. This study examined whether Dutch children who received online treatment progressed as much in their reading and spelling performance as children who received the usual face-to-face treatment. To this end, 254 children who received treatment-as-usual were compared to 162 children who received online treatment with Bayesian methods. The advantage of a Bayesian approach is that it can provide evidence for and against the null hypothesis whereas frequentist approaches only provide evidence against it. We found that children in the online treatment condition received slightly fewer treatment sessions but progressed equally after controlling for the number of sessions compared to the treatment-as-usual condition. These results have clinical and practical implications as they show that reading treatment can be successfully delivered online.
The unifying theme of the present invention is the description of a class of proteins present in human blood which have the capacity to selectively recognize and induce apoptosis of cells which convey abnormal surface carbohydrates. Alterations in cellular glycosylation can result from either species-specific differences or may reflect cancer-associated changes. Human serum carbohydrate binding proteins, referred to as lectins, were isolated on several different carbohydrate columns including Gal alpha (papGal), GalNAc, GlcNAc, Fucose, Mannose and Melibiose. These lectins were shown to cause apoptosis of porcine aortic endothelial cells. This demonstrates a new pathway leading to endothelial cell death following xenogenic stress that may be important in the pathogenesis of xenograft rejection and suggests new therapeutic approaches to the treatment of xenograft rejection. Further, these mammalian carbohydrate binding proteins are herein shown to cause apoptosis of breast cancer and lung cancer cells in vitro, and can be used as a cytotoxic agent against human tumour cells. Significantly, the proteins of the present invention exhibit minimal binding or reactivity against normally glycosylated human cells. This invention also relates to a novel bioassay for the detection and quantitation of cellular apoptosis in vitro, and to the utility of this assay for the identification and evaluation of compounds with potential apogenic activity.
Quetiapine is an antagonist at multiple neurotransmitter receptors in the brain: serotonin 5HT and 5HT (IC =717 & 148nM, respectively), dopamine D and D (IC =1268 & 329nM, respectively), histamine H (IC50=30nM), and adrenergic α1 and α2receptors (IC =94 & 271nM, respectively). Quetiapine has no appreciable affinity at cholinergic muscarinic and benzodiazepine receptors (IC > 5000 nM). 1A250s1250s150s50s

Effect on QT Interval

In clinical trials quetiapine was not associated with a persistent increase in QT intervals. However, the QT effect was not systematically evaluated in a thorough QT study. In post marketing experience there were cases reported of QT prolongation in patients who overdosed on quetiapine [ ], in patients with concomitant illness, and in patients taking medicines known to cause electrolyte imbalance or increase QT interval. see Overdosage (10.1)
The primary objective of this clinical trial is to investigate the effectiveness and safety of high-frequency repetitive transcranial magnetic stimulation (rTMS) in the cerebellum for individuals with post-stroke cognitive impairment. The trial aims to answer two main questions: (1) What is the effectiveness of high-frequency rTMS in improving post-stroke cognitive impairment? (2) Is high-frequency rTMS in the cerebellum safe for individuals with post-stroke cognitive impairment? Participants will undergo 5Hz rTMS in the cerebellar opposite the lesion site, once daily for a total of five days. The control group will receive sham rTMS with the same parameters and positions. By comparing the effectiveness of rTMS for post-stroke cognitive impairment between the two groups, researchers will assess the potential benefits of rTMS.
Nucleases and methods of using these nucleases for alteration of a CFTR gene and generation of cells and animal models. In one aspect, described herein is a zinc-finger protein (ZFP) that binds to target site in a CFTR gene in a genome, wherein the ZFP comprises one or more engineered zinc-finger binding domains. In one embodiment, the ZFP is a zinc-finger nuclease (ZFN) that cleaves a target genomic region of interest, wherein the ZFN comprises one or more engineered zinc-finger binding domains and a nuclease cleavage domain or cleavage half-domain. Cleavage domains and cleavage half domains can be obtained, for example, from various restriction endonucleases and/or homing endonucleases. In one embodiment, the cleavage half-domains are derived from a Type IIS restriction endonuclease (e.g., Fok I). In certain embodiments, the zinc finger domain recognizes a target site in a CFTR gene.
The management of metastatic castrate-resistant prostate cancer (mCRPC) has evolved in the past decade due to substantial advances in understanding the genomic landscape and biology underpinning this form of prostate cancer. The implementation of various therapeutic agents has improved overall survival but despite the promising advances in therapeutic options, mCRPC remains incurable. The focus of treatment should be not only to improve survival but also to preserve the patient's quality of life (QoL) and ameliorate cancer-related symptoms such as pain. The choice and sequence of therapy for mCRPC patients are complex and influenced by various factors, such as side effects, disease burden, treatment history, comorbidities, patient preference and, more recently, the presence of actionable genomic alterations or biomarkers. Docetaxel is the first-line treatment for chemo-naïve patients with good performance status and those who have yet to progress on docetaxel in the castration-sensitive setting. Novel androgen agents (NHAs), such as abiraterone and enzalutamide, are effective treatment options that are utilized as second-line options. These medications can be considered upfront in frail patients or patients who are NHA naïve. Current guidelines recommend genetic testing in mCRPC for mutations in DNA repair deficiency genes to inform treatment decisions, as for example in breast cancer gene mutation testing. Other potential biomarkers being investigated include phosphatase and tensin homologues and homologous recombination repair genes. Despite a growing number of studies incorporating biomarkers in their trial designs, to date, only olaparib in the PROFOUND study and lutetium-177 in the VISION trial have improved survival. This is an unmet need, and future trials should focus on biomarker-guided treatment strategies. The advent of novel noncytotoxic agents has enhanced targeted drug delivery and improved treatment responses with favourable toxicity profiling. Trials should continue to incorporate and report health-related QoL scores and functional assessments into their trial designs.
BACKGROUND: Early identification of a patient with infection who may develop sepsis is of utmost importance. Unfortunately, this remains elusive because no single clinical measure or test can reflect complex pathophysiological changes in patients with sepsis. However, multiple clinical and laboratory parameters indicate impending sepsis and organ dysfunction. Screening tools using these parameters can help identify the condition, such as SIRS, quick SOFA (qSOFA), National Early Warning Score (NEWS), or Modified Early Warning Score (MEWS). We aim to externally validate qSOFA, SIRS, and NEWS/NEWS2/MEWS for in-hospital mortality among adult patients with suspected infection who presenting to the emergency department.
METHODS AND ANALYSIS: PASSEM study is an international prospective external validation cohort study. For 9 months, each participating center will recruit consecutive adult patients who visited the emergency departments with suspected infection and are planned for hospitalization. We will collect patients' demographics, vital signs measured in the triage, initial white blood cell count, and variables required to calculate Charlson Comorbidities Index; and follow patients for 90 days since their inclusion in the study. The primary outcome will be 30-days in-hospital mortality. The secondary outcome will be intensive care unit (ICU) admission, prolonged stay in the ICU (i.e., ≥72 hours), and 30- as well as 90-days all-cause mortality. The study started in December 2021 and planned to enroll 2851 patients to reach 200 in-hospital death. The sample size is adaptive and will be adjusted based on prespecified consecutive interim analyses.
DISCUSSION: PASSEM study will be the first international multicenter prospective cohort study that designated to externally validate qSOFA score, SIRS criteria, and EWSs for in-hospital mortality among adult patients with suspected infection presenting to the ED in the Middle East region.
STUDY REGISTRATION: The study is registered at ClinicalTrials.gov (NCT05172479).
PURPOSE:To provide the titled agent containing a diphthalic acid ester derivative or its addition salt as an active component. CONSTITUTION:An analgesic, anti-inflammatory and anti-allergic agent is produced by using a compound of formula I (X is residue of formula II, formula III or formula IV) (e.g. olean-120-ene,3beta-30-diol 3beta,30-di-o-hemiphthalate) or its addition salt as an active component. The compound of formula I can be produced by reacting the compound of formula II-formula IV with phthalic anhydride in a basic organic solvent such as pyridine, triethylamine, etc. It can be administered orally or parenterally. Dose for oral administration is 50-300mg daily per person and dose for parenteral administration is preferably 50% of the dose for oral administration. It can be used in the form of power, granule, tablet, sugar-coated tablet, etc., by compounding with an excipient (e.g. lactose, starch, etc.).
The invention discloses a saccharomyces cerevisiae expression long-acting recombinant type III collagen and application thereof in cosmetics. The amino acid sequence of the long-acting recombinant type III collagen comprises a basic repeating unit and a terminal amino acid sequence. The basic repeating unit comprises a human type III collagen peptide segment, and the amino acid sequence of the human type III collagen peptide segment is as follows: GERGAPGFRGPAGPNGIPGEKGPAGERGAP are provided. The terminal amino acid sequence comprises a human type II collagen peptide section, and the amino acid sequence of the human type II collagen peptide section is as follows: GPPGPCCGGG are provided. The long-acting recombinant type III collagen has good biocompatibility and cell adhesion, can promote the formation of new cells, has the function of stopping bleeding, and has stronger function of promoting the growth of epithelial cells. Compared with collagen extracted from animal tissues and xenogenees, the long-acting recombinant type III collagen has the advantages of solubility, no virus hidden trouble and low rejection reaction.
ERMEZA oral solution may have a different concentration from other levothyroxine oral solution products. Use caution and consider the total dosage in terms of mcg and not volume (mL) when converting between ERMEZA and other levothyroxine oral solution products.

The dosage of ERMEZA for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food and the specific nature of the condition being treated [see Dosage and Administration (2.3), Warnings and Precautions (5), and Drug Interactions (7)]. Dosing must be individualized to account for these factors and dose adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see Dosage and Administration (2.5)]. 

For adult patients with primary hypothyroidism, titrate until the patient is clinically euthyroid and the serum TSH returns to normal [see Dosage and Administration (2.3)]. 

For secondary or tertiary hypothyroidism, serum TSH is not a reliable measure of ERMEZA dosage adequacy and should not be used to monitor therapy. Use the serum free-T4 level to titrate ERMEZA dosing until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range [see Dosage and Administration (2.3)].

The peak therapeutic effect of a given dose of ERMEZA may not be attained for 4 to 6 weeks.
Atherosclerosis is a leading cause of death in the world. A significant body of evidence suggests that inflammation and various players are implicated and have pivotal roles in the formation of atherosclerotic plaques. Toll-like receptor 4 (TLR4) is linked with different stages of atherosclerosis. This receptor is highly expressed in the endothelial cells (ECs) and atherosclerotic plaques. TLR4 activation can lead to the production of inflammatory cytokines and related responses. Lectin-like oxidized low-density lipoprotein-1 (LOX-1), an integral membrane glycoprotein with widespread expression on the ECs, is involved in atherosclerosis and has some common pathways with TLR4 in atherosclerotic lesions. In addition, proprotein convertase subtilisin/kexin type9 (PCSK9), which is a regulatory enzyme with different roles in cholesterol uptake, is implicated in atherosclerosis. At present, TLR4, PCSK9, and LOX-1 are increasingly acknowledged as key players in the pathogenesis of atherosclerotic cardiovascular diseases. Herein, we presented the current evidence on the structure, functions, and roles of TLR4, PCSK9, and LOX-1 in atherosclerosis.